Innate immunity
Increase · moderate
Antimicrobial peptide activity
Literature evidence
Compound library
Vivy evidence dossier
LL-37
Also indexed as LL-37, Cathelicidin, CAMP
T3Peptides
Read this entry as context, not instruction.
Evidence labels describe the material available in this reference entry. They do not establish that a compound is appropriate, effective, or safe for you. Inclusion is not a recommendation to use it.
Reference context
Pharmacokinetic context
Half-life2 hr
This field summarizes the library record. Half-life can vary with formulation, indication, and individual clinical context.
Observed relationships
Biomarker context
Wound healing
Increase · moderate
Promotes tissue repair signaling
Literature evidence
Pathogen load
Decrease · moderate
Direct antimicrobial effects
Literature evidence
IL-8
Modulate · small
Chemotactic immune signaling
Literature evidence
CRP
Decrease · small
Reduces inflammatory burden in infection
Literature evidence
Biofilm formation
Decrease · small
Disrupts microbial biofilms
Literature evidence
Skin barrier function
Increase · small
Enhances epithelial defense
Literature evidence
Neutrophil activity
Increase · small
Supports innate immune response
Literature evidence
Keep in view
Safety discussion points
LL-37 is a cathelicidin antimicrobial peptide (CAMP) with immune-modulating, wound healing, and antimicrobial properties. Not FDA-approved.
Keep the reference close
Track LL-37 in context.
Hey Vivy helps you organize protocols and review change over time. It does not diagnose, prescribe, or replace qualified care.